Camber Capital Management LP
Reported holdings as of Q2 2025, from 27 quarterly filings.
This filer last reported in Q2 2025; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| STATE STR SPDR S&P 500 ETF T OPT | SPY | $308.9M | options only | -0.81pp | 7q | OPTIONS | |
| ZIMMER BIOMET HOLDINGS INC | ZBH | $91.2M | 1,000,000 | -0.48pp | 16q | -55.6%-$114.0M | |
| BAXTER INTL INC | BAX | $86.3M | 2,850,000 | +1.11pp | 10q | -50.4%-$87.8M | |
| HUMANA INC | HUM | $73.3M | 300,000 | +0.07pp | 5q | -58.6%-$103.9M | |
| CVS HEALTH CORP | CVS | $72.4M | 1,050,000 | +1.38pp | 5q | -53.3%-$82.8M | |
| GLOBUS MED INC | GMED | $47.2M | 800,000 | +1.18pp | 10q | -36.0%-$26.6M | |
| ICON PUB LTD CO | ICLR | $43.6M | 300,000 | - | new | NEW | |
| ASCENDIS PHARMA A/S | ASND | $43.1M | 250,000 | +2.11pp | 4q | -28.6%-$17.3M | |
| MERCK & CO INC | MRK | $39.6M | 500,000 | - | new | NEW | |
| GSK PLC OPT | GSK | $38.4M | options only | +2.23pp | 12q | OPTIONS | |
| PFIZER INC | PFE | $36.4M | 1,500,000 | -4.96pp | 3q | -40.0%-$24.2M | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $33.0M | 600,000 | +1.84pp | 3q | +20.0%+$5.5M | |
| UNITEDHEALTH GROUP INC | UNH | $31.2M | 100,000 | - | new | NEW | |
| VIATRIS INC | VTRS | $24.6M | 2,750,000 | -0.02pp | 19q | -63.3%-$42.4M | |
| BROOKDALE SR LIVING INC | BKD | $15.0M | 2,150,000 | +0.01pp | 27q | -65.6%-$28.5M | |
| ZIMVIE INC | ZIMV | $15.0M | 1,600,000 | +0.68pp | 14q | -15.1%-$2.7M | |
| APELLIS PHARMACEUTICALS INC | APLS | $14.7M | 850,000 | - | new | NEW | |
| MYRIAD GENETICS INC | MYGN | $10.6M | 2,000,000 | +0.26pp | 24q | -14.9%-$1.9M | |
| EVOLENT HEALTH INC | EVH | $9.6M | 850,000 | -0.11pp | 5q | -71.7%-$24.2M | |
| CONCENTRA GROUP HOLDINGS PAR | CON | $8.2M | 400,000 | -0.46pp | 4q | -75.0%-$24.7M | |
| INOGEN INC | INGN | $6.9M | 975,000 | +0.40pp | 15q | HELD | |
| DENALI THERAPEUTICS INC | DNLI | $5.6M | 400,000 | -0.08pp | 6q | -68.0%-$11.9M | |
| THERAVANCE BIOPHARMA INC | TBPH | $5.0M | 450,000 | +0.15pp | 6q | -55.0%-$6.1M | |
| ANAPTYSBIO INC | ANAB | $2.8M | 125,000 | -0.23pp | 3q | -83.3%-$13.9M | |
| ORASURE TECHNOLOGIES INC | OSUR | $2.7M | 900,000 | +0.15pp | 20q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Funds & ETFs | $308.9M | 29.0% |
| Biotech & Pharma | $282.6M | 26.5% |
| Medical Devices | $234.3M | 22.0% |
| Insurance | $104.5M | 9.8% |
| Healthcare Services | $95.6M | 9.0% |
| Other sectors | $9.6M | 0.9% |
| Not classified | $29.7M | 2.8% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | $1.1B | 25 | 4 | 1 | 16 | 10 | 79.2% | 45 |
| Q1 2025 | $2.8B | 31 | 2 | 7 | 16 | 8 | 80.5% | 45 |
| Q4 2024 | $4.3M | 37 | 8 | 8 | 6 | 4 | 72.8% | 45 |
| Q3 2024 | $3.1M | 33 | 4 | 7 | 8 | 8 | 68.4% | 45 |
| Q2 2024 | $3.6M | 37 | 6 | 7 | 9 | 5 | 67.4% | 45 |
| Q1 2024 | $4.1M | 36 | 6 | 5 | 7 | 8 | 70.4% | 45 |
| Q4 2023 | $3.9M | 38 | 6 | 11 | 9 | 8 | 70.0% | 45 |
| Q3 2023 | $3.0M | 40 | 5 | 14 | 10 | 3 | 57.5% | 45 |
| Q2 2023 | $3.1M | 38 | 2 | 11 | 8 | 5 | 63.1% | 45 |
| Q1 2023 | $3.3M | 41 | 8 | 9 | 7 | 5 | 66.0% | 45 |
| Q4 2022 | $2.9M | 38 | 6 | 11 | 10 | 12 | 65.7% | 45 |
| Q3 2022 | $3.3B | 44 | 9 | 18 | 7 | 5 | 53.4% | 45 |
| Q2 2022 | $2.3B | 40 | 10 | 12 | 5 | 7 | 58.9% | 46 |
| Q1 2022 | $2.8B | 37 | 8 | 20 | 5 | 8 | 57.7% | 46 |
| Q4 2021 | $2.9B | 37 | 6 | 10 | 14 | 5 | 62.6% | 45 |
| Q3 2021 | $3.2B | 36 | 9 | 11 | 8 | 5 | 54.3% | 46 |
| Q2 2021 | $3.0B | 32 | 6 | 11 | 7 | 6 | 53.3% | 47 |
| Q1 2021 | $2.9B | 32 | 11 | 5 | 8 | 10 | 62.6% | 47 |
| Q4 2020 | $2.8B | 31 | 6 | 3 | 22 | 11 | 59.2% | 47 |
| Q3 2020 | $3.8B | 36 | 11 | 24 | 1 | 5 | 63.8% | 47 |
| Q2 2020 | $1.7B | 30 | 9 | 6 | 9 | 8 | 69.0% | 45 |
| Q1 2020 | $1.7B | 29 | 8 | 12 | 6 | 7 | 63.2% | 45 |
| Q4 2019 | $2.0B | 28 | 5 | 6 | 6 | 9 | 58.3% | 45 |
| Q3 2019 | $1.9B | 32 | 8 | 10 | 6 | 5 | 60.1% | 45 |
| Q2 2019 | $2.1B | 29 | 7 | 9 | 6 | 6 | 67.5% | 45 |
| Q1 2019 | $2.0B | 28 | 4 | 8 | 6 | 10 | 62.6% | 45 |
| Q4 2018 | $2.1B | 34 | 0 | 0 | 0 | 0 | 60.1% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.